ICON Public Limited Company (NASDAQ:ICLR) is a leading healthcare intelligence and clinical research organization innovating next-gen therapies for better patient outcomes. The company outsources ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Fintel reports that on April 14, 2025, TD Cowen downgraded their outlook for ICON Public Limited (NasdaqGS:ICLR) from Buy to Hold. Analyst Price Forecast Suggests 68.84% Upside As of April 2, 2025, ...

NEW YORK, NY / ACCESS Newswire / April 10, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to ...

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Over the past few years, many clinical study administrators wanted to use ... J.C. led product teams at Bioclinica and ICON. He holds a Bachelor’s degree from Baldwin Wallace University and ...

OncLive® Launches Scout, an AI Assistant to Help Oncologists Quickly Access Expert Insights ...

ICON's two largest customers were diversifying their clinical research organization providers away from the Company; (f)as a result of (a)-(e) above, ICON's reported net new business awards and ...

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 11, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors ...

The global bioanalytical testing services market was worth USD 2.7 billion in 2020 and is further projected to reach USD 6.1 billion by 2027, at a CAGR of 12.1% during the forecast period (2021-2027).